Raymond James Financial
AXSM icon

Raymond James Financial’s Axsome Therapeutics AXSM Stock Holding History

Raymond James Financial’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.1M Buy
155,855
+8,089
+5% +$1.75M 0.01% 1092
2026
Q1 		$24.3M Sell
147,766
-2,332
-2% -$403K 0.01% 1333
2025
Q4 		$24.8M Sell
150,098
-8,591
-5% -$1.2M 0.01% 1290
2025
Q3 		$19.3M Sell
158,689
-2,723
-2% -$307K 0.01% 1437
2025
Q2 		$16.8M Buy
161,412
+6,337
+4% +$671K 0.01% 1494
2025
Q1 		$18.1M Sell
155,075
-19,511
-11% -$2.22M 0.01% 1384
2024
Q4 		$14.8M Buy
+174,586
New +$16.1M 0.01% 1532

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Raymond James Financial's AXSM Position: Q2 2026 in Review

Raymond James Financial increased its Axsome Therapeutics (AXSM) stake by 5.5% in Q2 2026, buying an estimated $1.75M and bringing the position to 155,855 shares worth $38.1M. The position accounts for 0.01% of the portfolio, ranked #1092.

Raymond James Financial first reported a position in AXSM in Q4 2024 and has held it in 7 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Raymond James Financial held 155,855 shares of Axsome Therapeutics worth $38.1M as of Q2 2026.
  • Raymond James Financial bought 8,089 Axsome Therapeutics shares in Q2 2026, an estimated $1.75M.
  • Axsome Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q2 2026, its #1092 holding.
  • Raymond James Financial first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.